These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32037096)

  • 1. Predicting the Pharmacokinetic Characteristics of Edaravone Intravenous Injection and Sublingual Tablet Through Modeling and Simulation.
    Chen X; Sun Z; Wang J; Liang W; Zhao X; Wang Y; Wang Y
    Clin Ther; 2020 Mar; 42(3):428-438. PubMed ID: 32037096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of Edaravone Sublingual Tablet Versus Intravenous Infusion in Healthy Male Volunteers.
    Wang J; Chen X; Yuan B; Wang W; Xu C; Zhao W; Zhao P; Wang Y; Zhao X; Wang Y
    Clin Ther; 2018 Oct; 40(10):1683-1691. PubMed ID: 30241688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Pharmacokinetics, Safety, and Drug-Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults.
    Shimizu H; Nishimura Y; Shiide Y; Matsuda H; Akimoto M; Matsuda M; Nakamaru Y; Kato Y; Kondo K
    Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1174-1187. PubMed ID: 33704925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects.
    Shimizu H; Nishimura Y; Shiide Y; Yoshida K; Hirai M; Matsuda M; Nakamaru Y; Kato Y; Kondo K
    Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1188-1197. PubMed ID: 33955162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers.
    Willsie SK; Evashenk MA; Hamel LG; Hwang SS; Chiang YK; Palmer PP
    Clin Ther; 2015 Jan; 37(1):145-55. PubMed ID: 25544247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations.
    Nakamaru Y; Kinoshita S; Kawaguchi A; Takei K; Palumbo J; Suzuki M
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):80-87. PubMed ID: 28872908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of the primary determining factor(s) governing the oral absorption of edaravone in rats.
    Hyung S; Jeong YS; Yeo J; Song YK; Kim MS; Im YJ; Maeng HJ; Chung SJ
    Eur J Pharm Sci; 2018 Oct; 123():312-320. PubMed ID: 30056192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-nanomicellizing solid dispersion of edaravone: part I - oral bioavailability improvement.
    Parikh A; Kathawala K; Tan CC; Garg S; Zhou XF
    Drug Des Devel Ther; 2018; 12():2051-2069. PubMed ID: 30013324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Edaravone for the treatment of amyotrophic lateral sclerosis.
    Yoshino H
    Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration.
    Kalluri HV; Zhang H; Caritis SN; Venkataramanan R
    Br J Clin Pharmacol; 2017 Nov; 83(11):2458-2473. PubMed ID: 28688108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
    Fabre MA; Fuseau E; Ficheux H
    J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal function in amyotrophic lateral sclerosis patients on long-term treatment with edaravone.
    Kakimoto A; Ishizaki M; Ueyama H; Maeda Y; Ueda M
    Medicine (Baltimore); 2021 May; 100(21):e26127. PubMed ID: 34032759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
    Bhandari R; Kuhad A; Kuhad A
    Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral Edaravone - Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis.
    Pattee GL; Genge A; Couratier P; Lunetta C; Sobue G; Aoki M; Yoshino H; Jackson CE; Wymer J; Salah A; Nelson S
    Expert Rev Neurother; 2023; 23(10):859-866. PubMed ID: 37646130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine.
    Lim SCB; Schug S; Krishnarajah J
    Pain Med; 2019 Jan; 20(1):143-152. PubMed ID: 29309700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two high-performance liquid chromatography-tandem mass spectrometry methods for determination of edaravone and taurine in human plasma: Application to drug-drug interaction and pharmacokinetic studies.
    Li L; Zhao S; Xu L; Su Y; Ding L
    J Sep Sci; 2020 Jun; 43(12):2279-2289. PubMed ID: 32175680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions.
    Li H; Xu K; Wang Y; Zhang H; Li T; Meng L; Gong X; Zhang H; Ou N; Ruan J
    Drugs R D; 2012 Jun; 12(2):65-70. PubMed ID: 22762844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.
    Dash RP; Babu RJ; Srinivas NR
    Clin Pharmacokinet; 2018 Nov; 57(11):1385-1398. PubMed ID: 29682695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Edaravone, a Free Radical Scavenger, Delayed Symptomatic and Pathological Progression of Motor Neuron Disease in the Wobbler Mouse.
    Ikeda K; Iwasaki Y
    PLoS One; 2015; 10(10):e0140316. PubMed ID: 26469273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
    Genge A; Pattee GL; Sobue G; Aoki M; Yoshino H; Couratier P; Lunetta C; Petri S; Selness D; Bidani S; Hirai M; Sakata T; Salah A; Apple S; Wamil A; Kalin A; Jackson CE
    Muscle Nerve; 2023 Feb; 67(2):124-129. PubMed ID: 36504406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.